M

allinckrodt has agreed to pay $35 million to settle charges of failing to report suspicious orders of controlled substances, the largest such deal involving a drug maker for such an infraction.

The deal also includes what authorities are calling a “groundbreaking parallel agreement” with the Drug Enforcement Agency, which will involve collecting and analyzing data from customers in order to identify suspicious sales.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.